Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00071
|
|||||
Drug Name |
Valsartan
|
|||||
Synonyms |
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid; Aventis brand of valsartan; CEPA brand of valsartan; CGP 48933; CGP-48933; Diovan; Diovan (TN); Diovan, Valsartan; Esteve brand of valsartan; Kalpress; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI); Lacer brand of valsartan; Miten; N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine; Nisis; Novartis brand of valsartan; Provas; Sanol brand of valsartan; Schwarz brand of valsartan; Tareg; Vals; Valsarran; Valsartan (JAN/USAN/INN); Valsartan [USAN:INN]; Valtan (TN); Valzaar (TN); Walsartan
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | High blood pressure [ICD11: BA00] | Approved | [1] | |||
Therapeutic Class |
Antihypertensive Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C24H29N5O3
|
|||||
Canonical SMILES |
CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O
|
|||||
InChI |
InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
|
|||||
InChIKey |
ACWBQPMHZXGDFX-QFIPXVFZSA-N
|
|||||
CAS Number |
CAS 137862-53-4
|
|||||
Pharmaceutical Properties | Molecular Weight | 435.5 | Topological Polar Surface Area | 112 | ||
Heavy Atom Count | 32 | Rotatable Bond Count | 10 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
XLogP |
4.4
|
|||||
PubChem CID | ||||||
PubChem SID |
103292815
, 103979540
, 104253413
, 104321799
, 11066615
, 11364700
, 11367262
, 11369824
, 11373100
, 11374217
, 11377988
, 11484996
, 11488936
, 11491646
, 11492564
, 11495610
, 117541337
, 117664453
, 119526522
, 123055291
, 124659015
, 124757534
, 124800101
, 125164338
, 14856825
, 14881173
, 26612829
, 26719825
, 43118184
, 46386599
, 46509000
, 46530915
, 47499543
, 48393917
, 49681716
, 49830875
, 50062253
, 50467452
, 53787275
, 57314146
, 7847466
, 81093312
, 85788951
, 90452226
, 92124805
, 92308052
, 92308462
, 92711441
, 93166503
, 99228303
|
|||||
ChEBI ID |
ChEBI:9927
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [3] | ||
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [4] | ||
OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [2] | ||
PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [5] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | MRP2 | Transporter Info | Km = 30.4 microM | LLC-PK1 cells-MRP2 | [2] | |
OATP1B1 | Transporter Info | Km = 17.8 microM | Chinese hamster ovary (CHO) cells-OATP1B1 | [6] | ||
OATP1B1 | Transporter Info | Km = 1.39 microM | Human embryonic kidney cells (HEK293)-OATP1B1 | [2] | ||
OATP1B3 | Transporter Info | Km = 23.5 microM | Chinese hamster ovary (CHO) cells-OATP1B3 | [6] | ||
OATP1B3 | Transporter Info | Km = 18.2 microM | Human embryonic kidney cells (HEK293)-OATP1B3 | [2] | ||
References | ||||||
1 | Valsartan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54. | |||||
3 | Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8. | |||||
4 | Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855. | |||||
5 | High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9. | |||||
6 | Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.